Another study indicated that the m6A modification induced by ‘eraser’ FTO augments melanoma growth, whereas FTO inhibition increases the sensitivity of cancer cells to anti-PD-1 immunotherapy, suggesting that the immune checkpoint molecular inhibitors represented by PD-1/PD-L1 can play an important role with the help of FTO inhibitors (Yang et al., 2019). Here, FTO is linked to cancer.